Abstract: The disclosure relates to pharmaceutical compositions and methods of using pharmaceutical compositions comprising effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (IL-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (IL-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (IL-1Ra) gene within synovial cells is regulated by an inflammation-sensitive promoter.

Abstract: In various examples, a plurality of poses corresponding to one or more configuration parameters within an environment—such as a location of a machine within an environment, an orientation of a machine within an environment, a sensor angle pose of a machine, or a sensor location of a machine—may be used to generate training data and corresponding ground truth data for training a machine learning model—such as a deep neural network (DNN). As a result, the machine learning model, once deployed, may more accurately compute one or more outputs—such as outputs representative of lane boundaries, trajectories for an autonomous machine, etc.—agnostic to machine and/or sensor poses of the machine within which the machine learning model is deployed.

Abstract: The disclosure relates to pharmaceutical compositions and methods of using pharmaceutical compositions comprising effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (IL-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (IL-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (IL-1Ra) gene within synovial cells is regulated by an inflammation-sensitive promoter.

Abstract: There are provided an apparatus and a method for eliminating water and particulate pollutant contained in a waste lubricant. The waste lubricant heated up to a proper temperature is injected into a vacuum chamber through a nozzle, the vacuum chamber maintaining a predetermined degree of vacuum. The water contained in the waste lubricant is vaporized according to a relationship between a vaporizing temperature of the waste lubricant and a vaporizing temperature of the water contained in the waste lubricant. The vaporized water is transformed into condensate water while passing through a condenser, and is stored in a water storage container. In addition, the waste lubricant, from which water is eliminated, is introduced into a waste lubricant discharging chamber by discharging means, and is passed through an electrostatic separator by an oil pump, to collect particulate pollutant.